A carregar...
Publicação
Avaliação de tecnologias de saúde: análise comparativa de metodologias inovadoras para financiamento a nível europeu
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 4.09 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
A Avaliação de Tecnologias de Saúde é um processo de avaliação terapêutico e económico complexo, onde se incluem medicamentos, dispositivos médicos e terapêuticas avançadas. É através dele que as tecnologias de saúde são integradas nos Serviços Nacionais de Saúde permitindo disponibilizar aos doentes um cuidado de saúde equitativo, mas também uma sustentabilidade financeira dos países.
Este é um processo bastante heterogéneo atualmente na Europa, daí a necessidade de criação de grupos de trabalho conjuntos e colaborações para otimizar e agilizar os processos impedindo uma desigualdade tão acentuada no acesso. Surgem organizações como o caso da EUnetHTA que veio desencadear um conjunto de colaborações como a Baltic Procurement Initiative, Beneluxa Initiative, Fair and Affordable Pricing, Nordic Pharmaceutical Forum e La Valletta Declaration. É nestas plataformas de trocas de best practices que se discutem temáticas como os Managed Entry Agreements e novas formas de aumentar o financiamento para inovação no mercado farmacêutico.
A análise de dados de três países distintos entre si, Reino Unido (NICE), Alemanha (IQWIG e G-BA), Suécia (TLV) foi crucial para comparar as metodologias específicas utilizadas com a realidade portuguesa.
Em Portugal, a Avaliação de Tecnologias de Saúde é liderada pelo INFARMED, I.P. mais especificamente pelo Sistema Nacional de Avaliação de Tecnologias de Saúde (SiNATS).
Com base nesta comparação de metodologias investigou-se qual o mecanismo de acesso às terapêuticas para as doenças raras e o atual paradigma dos medicamentos órfãos bem como os desafios do seu acesso no setor. Analisou-se ainda dois case studies de situações que ocorreram em Portugal quais as suas lacunas e adversidades à data.
Por fim, podemos concluir que certas metodologias e best practices utilizadas na Avaliação de Tecnologias de Saúde noutros países podem ser experimentadas em Portugal com intuito de melhorar o acesso a terapêuticas inovadoras que estejam centradas no doente.
The Health Technology Assessment is a complex process composed by a therapeutic and economic evaluation of medicines, medical devices, and advanced therapeutical options. It is through this process that health technologies are integrated into the countries National Health Services, not only allowing patients to have access to innovative therapeutical options but also serving as a guarantee of the country’s financial sustainability. Due to the Health Technology Assessment being a heterogeneous process in Europe, there was an urge in creating working groups and collaborations between countries in order to optimize and facilitate these complex evaluations. As such, organizations like the EUnetHTA and collaborations like the Baltic Procurement Initiative, BeNeLuxA Initiative, Fair and Affordable Pricing, Nordic Pharmaceutical Forum and the La Valletta Declaration were created. The main objective of these platforms is to allow the exchange of best practices, the discussion of subjects like Managed Entry Agreements and new ways to increase the funding of new health technologies. A data analysis was conducted and focused on three major countries in Europe: United Kingdom (NICE), Germany (IQWIG and G-BA) and Sweden (TLV). Each of these countries Health Technology Assessment process was then compared with the one conducted in Portugal. In Portugal the Health Technology Assessment is Conducted by INFARMED, I.P. more precisely by the National System of Health Technology Assessment (SiNATS). The comparison was based in the paradigm and the mechanisms that each country conduct in order to guarantee access to orphan medicines for rare diseases and the current challenges that this sector faces in the evaluation of these same technologies. Following this comparison, two real world case studies that occurred in Portugal were also analyzed and their problems discussed. As such, we can conclude that some processes and best practices utilized in these three countries could be adopted in Portugal. With the main goal of improving the access to new health technologies that are centered in the patient outcome.
The Health Technology Assessment is a complex process composed by a therapeutic and economic evaluation of medicines, medical devices, and advanced therapeutical options. It is through this process that health technologies are integrated into the countries National Health Services, not only allowing patients to have access to innovative therapeutical options but also serving as a guarantee of the country’s financial sustainability. Due to the Health Technology Assessment being a heterogeneous process in Europe, there was an urge in creating working groups and collaborations between countries in order to optimize and facilitate these complex evaluations. As such, organizations like the EUnetHTA and collaborations like the Baltic Procurement Initiative, BeNeLuxA Initiative, Fair and Affordable Pricing, Nordic Pharmaceutical Forum and the La Valletta Declaration were created. The main objective of these platforms is to allow the exchange of best practices, the discussion of subjects like Managed Entry Agreements and new ways to increase the funding of new health technologies. A data analysis was conducted and focused on three major countries in Europe: United Kingdom (NICE), Germany (IQWIG and G-BA) and Sweden (TLV). Each of these countries Health Technology Assessment process was then compared with the one conducted in Portugal. In Portugal the Health Technology Assessment is Conducted by INFARMED, I.P. more precisely by the National System of Health Technology Assessment (SiNATS). The comparison was based in the paradigm and the mechanisms that each country conduct in order to guarantee access to orphan medicines for rare diseases and the current challenges that this sector faces in the evaluation of these same technologies. Following this comparison, two real world case studies that occurred in Portugal were also analyzed and their problems discussed. As such, we can conclude that some processes and best practices utilized in these three countries could be adopted in Portugal. With the main goal of improving the access to new health technologies that are centered in the patient outcome.
Descrição
Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, 2021, Universidade de Lisboa, Faculdade de Farmácia.
Palavras-chave
Avaliação de tecnologias de saúde Acesso ao mercado Financiamento Medicamentos órfãos Doenças raras Mestrado integrado - 2021